ERBB2 and breast cancer: We also performed the same analysis by breast cancer subtype, defined by HR and HER2 status, and substantial improvements in predicting RCB-III after adding shape features were observed in HR+/HER2- (from 0.56 to 0.70) and triple negatives (from 0.65 to 0.73).